In-vitro studies with ceftazidime.
MIC determinations for 275 multiply-resistant nosocomial isolates of enterobacteria showed that ceftazidime was more effective than cefotaxime, cefoxitin or cephalothin. Enterobacter species were the most resistant with 12% isolates resistant to more than 8 mg/l of ceftazidime, but this was still the most active agent. Of 150 isolates of Pseudomonas aeruginosa (55% of which were resistant to gentamicin), only 9% were resistant to 8 mg/l of ceftazidime and 2% to cefsulodin, both of which were more active than cefotaxime, ceftriaxone, cefoperazone or moxalactam. Ceftazidime was less active than cefoxitin against Bacteroides fragilis, with 30% of strains resistant to 8 mg/l of ceftazidime, but it was more active than cefotaxime or cephalothin.
First Department of Propedeutic Medicine, Athens University School of Medicine, King Paul's Hospital, Athens, 609, Greece.
H
H
Giamarellou
A
A
Avlami
V
V
Matsakas
J
J
Kosmidis
G K
GK
Daikos
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002442:Ceftazidime / Q000494:pharmacology*; D003428:Cross Infection / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D024901:Drug Resistance, Multiple, Bacterial; D004755:Enterobacteriaceae / Q000187:drug effects*; D004756:Enterobacteriaceae Infections / Q000382:microbiology; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests
D000900:Anti-Bacterial Agents; D002442:Ceftazidime